世界主要先進国におけるてんかん治療薬市場動向（～2019）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Disease Overview 9
2.2 Epidemiology 9
2.3 Symptoms 11
2.4 Etiology 11
2.5 Pathophysiology 12
2.6 Co-morbidities/Complications 12
2.7 Diagnosis 12
2.8 Prognosis 13
2.9 Treatment Efficacy 13
2.10 Treatment Options 14
2.10.1 Ion Channel Modulators 14
2.10.2 GABA-ergic Facilitation 15
2.10.3 Excitatory Amino Acid Inhibitors 15
2.10.4 Synaptic Modulators 15
2.11 Non-pharmacological Management 15
2.11.1 Lobectomy and Lesionectomy 15
2.11.2 Ketogenic Diet and Modified Atkins Diet 15
2.11.3 Vagus Nerve Stimulation 16
3 Epilepsy Therapeutic Landscape 17
3.1 Overview 17
3.2 Lyrica (pregabalin) 17
3.3 Lamictal (lamotrigine) 18
3.4 Keppra (levetiracetam) 19
3.5 Zonegran (zonisamide) 21
3.6 Vimpat (lacosamide) 22
3.7 Aptiom/Zebinix (eslicarbazepine acetate) 24
3.8 Fycompa (perampanel) 24
3.9 Trobalt/Potiga (ezogabine/retigabine) 25
3.10 Banzel/Inovelon (rufinamide) 26
3.11 Comparative Efficacy and Safety of Marketed Products 26
4 Pipeline for Epilepsy Therapeutics 29
4.1 Overall Pipeline 29
4.2 Pipeline by Mechanism of Action 31
4.3 Clinical Trials 32
4.3.1 Failure Rate 32
4.3.2 Patient Enrolment and Clinical Trial Size 34
4.3.3 Clinical Trial Duration 36
4.4 Promising Pipeline Candidates 38
4.4.1 Brivaracetam – UCB 38
4.4.2 Ganaxolone – Marinus Pharmaceuticals 38
5 Epilepsy Therapeutics Market Forecast to 2019 39
5.1 Geographical Markets 39
5.1.1 Major Developed Markets 39
5.1.2 The US 40
5.1.3 Top Five EU Countries 43
5.1.4 Japan 46
5.1.5 Canada 48
5.2 Drivers and Barriers 50
5.2.1 Drivers 50
5.2.2 Barriers 50
6 Deals and Strategic Consolidations 52
6.1 Deals Analysis 52
6.2 Research and Development Co-development Agreements 54
6.3 Research and Development Licensing Agreements 55
7 Appendix 57
7.1 Abbreviations 57
7.2 References 58
7.3 References for Heat Maps 62
7.4 Pipeline Products by Phase 63
7.4.1 Discovery 63
7.4.2 Preclinical 63
7.4.3 IND-filed and Phase 0 64
7.4.4 Phase I 65
7.4.5 Phase II 65
7.4.6 Phase III 66
7.4.7 Pre-registration 66
7.5 Market Forecasting Data Tables to 2019 67
7.5.1 Major Developed Markets 67
7.5.2 US 67
7.5.3 UK 67
7.5.4 France 68
7.5.5 Germany 68
7.5.6 Italy 68
7.5.7 Spain 69
7.5.8 Japan 69
7.5.9 Canada 69
7.6 Research Methodology 70
7.6.1 Coverage 70
7.6.2 Secondary Research 70
7.6.3 Primary Research 70
7.6.4 Therapeutic Landscape 71
7.6.5 Geographical Landscape 74
7.6.6 Pipeline Analysis 74
7.7 Expert Panel Validation 74
7.8 Contact Us 74
7.9 Disclaimer 74